A5034457278- Ovarian cancer diagnosis and treatment
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Colorectal Cancer Surgical Treatments
- Endometrial and Cervical Cancer Treatments
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Bladder and Urothelial Cancer Treatments
- Genetic Associations and Epidemiology
- Testicular diseases and treatments
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- Cancer-related cognitive impairment studies
- PARP inhibition in cancer therapy
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Ferroptosis and cancer prognosis
National Institute of Mental Health and Neurosciences
2023
Creative Commons
2023
University of North Carolina at Chapel Hill
2007-2023
Emory University
2023
University of Oklahoma Health Sciences Center
2023
Tufts University
2023
Boston University
2023
Cancer Research UK Clinical Trials Unit
2012-2022
Cancer Research UK
2013-2022
University of Glasgow
2013-2022
Since 2004, a regimen of 6 months treatment with oxaliplatin plus fluoropyrimidine has been standard adjuvant therapy in patients stage III colon cancer. However, since is associated cumulative neurotoxicity, shorter duration could spare toxic effects and health expenditures.
Purpose Persistent insomnia is a common complaint in cancer survivors, but seldom satisfactorily addressed. The adaptation to care of validated, cost-effective intervention may offer practicable solution. aim this study was investigate the clinical effectiveness protocol-driven cognitive behavior therapy (CBT) for insomnia, delivered by oncology nurses. Patients and Methods Randomized, controlled, pragmatic, two-center trial CBT versus treatment as usual (TAU) 150 patients (103 females; mean...
Abstract Aberrant epigenetic regulation, such as CpG island methylation and associated transcriptional silencing of genes, has been implicated in a variety human diseases, including cancer. Methylation genes involved apoptosis, the DNA mismatch repair (MMR) gene hMLH1, can occur tumor models resistance to chemotherapeutic drugs. However, relevance for acquired chemotherapy patients’ tumors remains unsubstantiated. Plasma from cancer patients, those with ovarian cancer, often contains...
Purpose Standard therapy for advanced ovarian cancer consists of a platinum agent in combination with taxane, which has 5-year survival rate approximately 45%. The large individual variability patients both outcome and toxicity risk from chemotherapy makes the identification pharmacogenetic markers that can be used to screen before selection an attractive prospect. Patients Methods We assessed 27 selected polymorphisms based on previously described associations or putative functional effects...
Purpose Studies indicate that ovarian cancer patients who have been optimally debulked survive longer. Although chemotherapy has variable, they defined standards of care. Additionally, it is suggested from the United Kingdom (UK) inferior survival compared with some other countries. We explored this within context a large, international, prospective, randomized trial first-line in advanced (docetaxel-carboplatin v paclitaxel-carboplatin; SCOTROC-1). The Scottish Randomised Trial Ovarian...
Upper gastrointestinal adenocarcinomas show an unexplained male predominance that is more apparent in oesophagus than stomach and intestinal diffuse histological subtype. We have conducted a population-based study to determine whether the gender phenomenon primarily related anatomical site or subtype.Of 3270 gastric oesophageal cancers recorded West of Scotland Cancer Registry, 1998-2002, 812 were randomly selected for detailed analysis. The Lauren subtype adenocarcinoma was determined by...
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
5502 Background: HGSOC is a histopathological diagnosis and may represent multiple diseases at molecular level. We investigated whether distinct subgroups influence treatment choice. Methods: mRNA was extracted from 265 macrodissected formalin fixed paraffin embedded HGSOCs Scottish patients (pts) treated with primary debulking then platinum based chemotherapy. Transcriptional analysis performed using the Ovarian DSA microarray. This repeated 283 UK samples ICON7 study [first line...
Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is acquisition DNA methylation. We therefore tested hypothesis hypomethylating agent 5-aza-2′-deoxycytodine (decitabine) can reverse to carboplatin women with relapsed cancer. Patients progressing 6–12 months after therapy were randomised decitabine on day 1 (AUC 6) 8, every 28 days or alone. The primary objective was response rate patients methylated...
Patients treated with standard chemotherapy for metastatic or relapsed cervical cancer respond poorly to conventional (response achieved in 20-30% of patients) an overall survival less than 1 year. High tumour angiogenesis and high concentrations intratumoural VEGF are adverse prognostic features. Cediranib is a potent tyrosine kinase inhibitor VEGFR1, 2, 3. In this trial, we aimed assess the effect addition cediranib carboplatin paclitaxel patients recurrent cancer.
The current study evaluated three biomarkers [homologous recombination deficiency (HRD), tumor BRCA1/2 (tBRCA) mutations, and CCNE1 copy-number variation (CNV)] in ovarian tumors from patients enrolled on the SCOTROC4 clinical trial for associations with outcome following carboplatin monotherapy. Ovarian (n = 250), high-grade serous (HGSOC) subgroup analysis 179) were classified as HRD positive (HRD score ≥42 or tBRCA mutation) amplification (CCNE1 CNV >2.4). Seventy-four (30%) positive,...
As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers.
Observational studies have reported a positive association between body mass index (BMI) and ovarian cancer risk. However, questions remain as to whether this represents causal effect, or holds for all histological subtypes. The lack of observed serous cancers may, instance, be due disease-associated weight loss. Mendelian randomization (MR) uses genetic markers proxies risk factors overcome limitations observational studies. We used MR elucidate the relationship BMI cancer, hypothesizing...